CIC
HAE icon

Chase Investment Counsel’s Haemonetics HAE Stock Holding History

Chase Investment Counsel’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,770
Closed -$1.68M – 129
2023
Q3 		$1.68M Buy
+18,770
New +$1.68M 0.84% 45

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Chase Investment Counsel's HAE Position: Q4 2023 in Review

Chase Investment Counsel sold out of Haemonetics (HAE) in Q4 2023, closing a stake of 18,770 shares — an estimated $1.68M sold.

Chase Investment Counsel first reported a position in HAE in Q3 2023 and held it in 1 quarter. The position peaked at $1.68M in Q3 2023. 295 funds tracked by Wall St. Rank hold HAE as of Q4 2023.

  • Chase Investment Counsel reported no remaining Haemonetics position as of Q4 2023 after selling out during the quarter.
  • Chase Investment Counsel sold 18,770 Haemonetics shares in Q4 2023, an estimated $1.68M.
  • Chase Investment Counsel first reported a position in Haemonetics in Q3 2023 and held it in 1 quarter.
  • Chase Investment Counsel's Haemonetics position peaked at $1.68M in Q3 2023.
  • 295 funds tracked by Wall St. Rank held Haemonetics as of Q4 2023.

Based on Chase Investment Counsel's 13F filing for Q4 2023, filed 5 Feb 2024.